AstraZeneca: Depressive Disorder, Major trials
The registry lists 35 Depressive Disorder, Major studies with AstraZeneca as lead sponsor. 0 are open to participants now and 13 have results posted.
Phase 1 2Phase 2 8Phase 3 14No phase 11(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive DisorderCompletedNCT01482221Phase 2Results posted
- A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.TerminatedNCT01288079Phase 2Results posted
- A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder.CompletedNCT01197508Phase 3Results posted
- A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive DisorderCompletedNCT01180400Phase 3Results posted
- A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD)CompletedNCT01157078Phase 3Results posted
- A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive DisorderCompletedNCT01153347Phase 3Results posted
- A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive DisorderCompletedNCT01152554Phase 3Results posted
- 6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive DisorderTerminatedNCT01145755Phase 2Results posted
- AZD7268 Safety and Tolerability StudyCompletedNCT01020799Phase 2Results posted
- This is a Study to Determine the Antidepressant Effects of AZD6765CompletedNCT00986479Phase 2Results posted
- Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD PatientsCompletedNCT00789854Phase 3Results posted
- Study of Antidepressant Efficacy of a Selective, High Affinity Enkephalinergic Agonist in Anxious Major Depressive Disorder (AMDD)CompletedNCT00759395Phase 2Results posted
- Efficacy and Safety Study of Seroquel SR in the Treatment of Major Depressive DisorderCompletedNCT00388973Phase 3Results posted
- Physician Survey on Monitoring of Patients Treated With QuetiapineCompletedNCT01795326
- EMR Data to Assess Monitoring of Patients Treated With QuetiapineCompletedNCT01793324
- European Drug Utilization StudyCompletedNCT01594996
- General Practice Research Database Seroquel XR Safety StudyCompletedNCT01447082
- Badalona Major Depressive Disorder Database StudyCompletedNCT01446692
- Description of Treatment Management of Patients With Major Depressive Disorder and Inadequate ResponseCompletedNCT01397903
- The Purpose of the Study is to Gain an In-depth Picture of the Patient Management and Prescription BehavioursCompletedNCT01377896
- Validation of the Spanish Version of the Clinically Useful Depression Outcome Scale (CUDOS) ScaleCompletedNCT01360307
- Determining Highest Dose Administration of TC-5214 and Evaluating Effect on the Electrical Activity in the HeartTerminatedNCT01359618Phase 1
- A Non Interventional Study to Investigating the Ratio of Mis-diagnosed Bipolar Symptoms in Patient With Major Depressive Disorder (MDD)CompletedNCT01344733
- PHARMO Institute Seroquel Safety StudyCompletedNCT01342120
- Study to Assess the Distribution, Metabolism and Excretion of [14C]AZD6765 After a Single-Dose Intravenous AdministrationCompletedNCT01217645Phase 1
- Antidepressant Incomplete Response DepressionCompletedNCT00782964
- AZD6765 Severe Major Depressive Disorder (MDD) IVCompletedNCT00781742Phase 2
- Efficacy of SEROQUEL in Selective Serotonin Reuptake Inhibitors (SSRI)-Resistant Major Depressive DisorderCompletedNCT00733668Phase 2
- Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive DisorderCompletedNCT00351910Phase 3
- Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive DisorderCompletedNCT00351169Phase 3
- Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in the Treatment of Major Depressive DisordersCompletedNCT00326144Phase 3
- Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in Combination With an Antidepressant in the Treatment of Major Depressive DisordersCompletedNCT00326105Phase 3
- Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo and Active Control in Major Depressive DisorderCompletedNCT00321490Phase 3
- Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Major Depressive DisorderCompletedNCT00320268Phase 3
- Quetiapine Fumarate as Monotherapy in the Maintenance Treatment of Patients With Major Depressive DisorderCompletedNCT00278941Phase 3